March 2025 Medicare IRA Inflation Reduction Act Drug Manufacturer Call Details
Relevant to: Enrollment and Payment Systems, Drug Pricing, Part D
Each week, we scan the latest CMS memos to find the most important ones that apply for PACE programs. Below is a summary of what you need to know.
Disclaimer: The content provided on this site is a summary for informational purposes only, and Grane PBM, Inc. assumes no liability for any errors or omissions in the site’s content. The information does not constitute legal or regulatory advice or replace the original CMS memo. Readers are advised to consult the CMS memo in its entirety and to verify information independently before making any decisions based on this information.
Click here to read the complete memo from CMS.
Introduction
The Centers for Medicare & Medicaid Services (CMS) has announced a special call for drug manufacturers regarding the implementation of the Medicare provisions outlined in the Inflation Reduction Act of 2022. This call, scheduled for March 25, 2025, will feature a demonstration of the Medicare Transaction Facilitator Data Module. The session aims to foster engagement, allowing manufacturers to ask questions and provide feedback, assisting in the seamless rollout of these new regulations.
Key Dates and Deadlines
- Date of Memorandum: March 7, 2025
- Next Call Date: March 25, 2025, from 1:00 PM – 2:30 PM EST
- Registration Closing Date: March 21, 2025, at 5:00 PM EST
PACE Compliance
This memo pertains to PACE programs in various ways, particularly because it deals with the implementation of the Medicare provisions of the Inflation Reduction Act. While the memo primarily addresses drug manufacturers, it could have indirect implications for PACE organizations if they interact with the manufacturers regarding Medicare-covered drugs.
It’s important for PACE organizations to stay informed of such updates because changes in Medicare provisions could affect drug pricing and reimbursement rates, impacting cost structures for these programs.
There are no specific PACE compliance requirements detailed in the memo; however, PACE organizations may need to pay attention to how these changes might influence their contractual relationships with drug manufacturers, especially if they are involved with the Medicare Coverage Gap Discount Program. Ensuring awareness of such implementation details can help PACE organizations align their practices with new Medicare provisions efficiently.
In summary, while there are no direct PACE compliance requirements mentioned, awareness and understanding of these new Medicare provisions as outlined in the memo could be beneficial for PACE organizations.
Required Actions
To ensure you are prepared and registered for the upcoming CMS call on March 25, 2025, follow these steps:
1. Submit any questions you have for the call by emailing IRARebateandNegotiation@cms.hhs.gov with the subject line “3/25 Discussion Question – Manufacturer” to ensure they are addressed during the session.
2. Register for the call by clicking on the registration link and ensure you complete the registration process before the deadline at 5:00 PM EST on March 21st. Make sure to use your HPMS Contract ID (P#) during registration if applicable.
3. If you encounter any issues with HPMS access or do not have a P# yet, contact the HPMS Access Help Desk at hpms_access@cms.hhs.gov for assistance or reach out to IRARebateandNegotiation@cms.hhs.gov to request access for manufacturers not yet covered under Medicare Part B.
FAQs
- “What is the purpose of the Medicare Transaction Facilitator Data Module (MTF DM)?”
- “How can drug manufacturers register for the March 25, 2025 CMS call?”
- “Who can attend the March 25, 2025, CMS call?”
- “What should be included in the email subject line when submitting questions for the call?”
- “How can manufacturers resolve issues accessing HPMS?”
